In the red zones of eastern Democratic Republic of Congo, a distinct and unusually lethal strain of Ebola has pushed the national risk assessment to “very high,” a troubling threshold not seen since the devastating West Africa outbreak a decade ago. By 21 May 2026, the World Health Organization (WHO) had recorded 746 suspected cases across Ituri, North Kivu and South Kivu provinces, with 176 suspected deaths among them. Confirmed figures stood at 83 cases and nine deaths in the DRC alone, with an additional two imported cases and one death in neighbouring Uganda. The outbreak, the third known to be caused by the Bundibugyo virus, has been declared a Public Health Emergency of International Concern.
The WHO’s revised risk assessment, announced on 22 May, elevates the national danger level to “very high” while retaining a “high” regional risk and a “low” global risk. However, as WHO Director of Health Emergency Alert & Response Operations Abdirahman Mahamud warned, “the potential of this virus spreading rapidly is high, very high, and that changed the whole dynamic.”
A Forgotten Strain with No Vaccine and No Cure
What distinguishes this outbreak from the many Ebola crises that have struck Central Africa is the identity of the pathogen itself. Unlike the well-studied Zaire strain, for which effective vaccines and monoclonal antibody treatments exist, Bundibugyo is a virological orphan. There is currently no approved vaccine for the Bundibugyo virus, and no licensed therapeutic has been proven effective against it. The two existing Ebola vaccines, rVSV-ZEBOV (Ervebo) and another pre-exposure candidate, were developed specifically for the Zaire strain and are not approved for use against Bundibugyo.
Discussions at the WHO are now under way to determine which experimental vaccine candidates could be fast-tracked for emergency clinical trials, but no timeline has been fixed. Similarly, the two monoclonal antibody treatments that proved lifesaving during the 2018‑2020 DRC outbreaks, REGN‑EB3 and mAb114, are specific to the Zaire virus and have shown no cross‑protection against Bundibugyo.
In the absence of specific antivirals, care relies on aggressive symptom management, fluid replacement, oxygen support and close monitoring of blood parameters, a difficult regimen to maintain in conflict affected, resource poor regions. An experimental oral drug, Obeldesivir, originally developed as a COVID-19 antiviral by Gilead Sciences, is being considered for post‑exposure prophylaxis among high‑risk contacts, but it remains unapproved and would require a “very, very strict protocol,” according to WHO Chief Scientist Sylvie Briand. The case fatality rate for Bundibugyo in previous outbreaks has ranged between 30 and 50 percent, substantially lower than the 90 percent lethality of Zaire, but still devastating in a population where health systems are already overwhelmed by armed violence and mass displacement.
Conflict, Mistrust and Misinformation
The outbreak is unfolding in what the UN has described as “conflict‑ravaged provinces,” where armed violence has intensified in recent months. More than 100,000 people have been newly displaced, and the UN estimates that across Ituri and North Kivu, four million people need urgent humanitarian assistance, two million are displaced, and ten million face acute hunger. The same insecurity that has plagued eastern DRC for decades now directly obstructs the Ebola response. Rapid response teams have faced restricted access, contact tracing has been hampered, and the standard PCR tests that work for Zaire cannot detect Bundibugyo, forcing delays as samples are sent to laboratories hundreds of miles away in Kinshasa.
Equally corrosive is the deep seated distrust of outside authorities. In a hospital in Rwampara on 21 May, an angry crowd set fire to Ebola treatment tents after authorities refused to release the body of a popular local footballer. His mother insisted that he had died of typhoid fever, not Ebola. The protest demonstrated why building community trust is not a secondary concern but a central pillar of epidemic control. The WHO regional director for Africa, Mohamed Yakub Janabi, warned that it would be “a big mistake to underestimate” the risk, noting that with the Bundibugyo strain, “we don’t have the vaccine.” The IFRC has been sending volunteers door-to-door to counter rumours and explain safe burial procedures, but suspicion remains high. As Gabriela Arenas, the IFRC’s regional operations coordinator, put it, “for others, there’s still suspicion and misinformation claiming that Ebola is fabricated.”
A Global Attention Deficit and the Lessons of Hantavirus
Janabi also pointed to a troubling disparity in international attention. An outbreak of hantavirus on a luxury cruise ship, which affected passengers from 23 countries, has received far more global media coverage than an Ebola outbreak that has already killed more people. “You just need one contact case to put all of us at risk,” he said, “so my wish and prayer is that we should give this the attention it deserves.”
The WHO has released 3.9 million from its contingency fund, and UN relief chief Tom Fletcher has allocated up to 60 million from the Central Emergency Response Fund. Yet the gap between the scale of the crisis and the resources committed remains glaring. A strategic preparedness and response plan is being finalised, but it will require sustained political will from donor nations.
A Race Against Time and the Law of the Jungle
The coming weeks will determine whether the Bundibugyo outbreak can be contained or whether it will expand into a larger regional catastrophe. WHO has deployed 22 international staff and is supporting the DRC and Ugandan authorities with contact tracing, treatment centre construction, risk communication and community engagement. A continental incident management support team has been established with Africa CDC. The WFP has begun moving responders and supplies, and the UN peacekeeping mission MONUSCO has airlifted nearly 30 tons of emergency supplies, including medicines, tents and protective equipment.
But in the absence of a vaccine and with a therapeutics pipeline that remains experimental, the response will depend on the oldest tools in the epidemiologist’s arsenal: isolation, contact tracing and safe burials. And those tools only work if the communities being asked to use them trust the hands that offer them. In the conflict ravaged east of the DRC, that trust has never been more fragile. The virus is spreading, and the world, distracted by distant wars is only beginning to notice.